All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

2012 Survey of RNs Released

November 13th 2012

Since last year, there has been significant improvement in career satisfaction.

FDA Grants Orphan Drug Status to Amatuximab for Malignant Pleural Mesothelioma

November 12th 2012

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.

Skin Exams

November 5th 2012

YouTube video provides guidance on assessing for skin cancer.

FDA Approves Synribo for CML

October 26th 2012

The FDA has approved omacetaxine mepesuccinate for the treatment of adult patients with Philadelphia chromosome-positive CML who have progressed after treatment with at least two prior TKIs.

Potential Biomarker for Response to Bevacizumab in Colorectal Cancer Identified

October 25th 2012

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Overuse of Procedures and Treatments

October 24th 2012

National summit convened to reduce overuse of unnecessary procedures and treatments.

Blood Test Monitors Response to Treatment in Metastatic Prostate Cancer

October 23rd 2012

A novel assay could determine when patients with metastatic prostate cancer begin to relapse on androgen deprivation therapy, and which patients may respond better to second-line therapies.

Axitinib Study Does Not Meet Primary Endpoint as Front-Line Therapy for Renal Cell Carcinoma

October 17th 2012

A phase III study of axitinib as a front-line therapy for metastatic renal cell carcinoma did not meet its primary endpoint of demonstrating a longer median progression-free survival than sorafenib.

Pink Overload

October 16th 2012

Does "think pink" actually raise awareness of breast cancer?

FDA Approves Nab-Paclitaxel for Advanced Lung Cancer

October 12th 2012

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

Gene Signatures Help Predict Aggressive Prostate Cancer

October 11th 2012

A whole-blood prognostic test based on gene-expression signatures may help predict risk for patients with castration-resistant prostate cancer.

Potency of Medications Beyond Their Expiration Date

October 9th 2012

Study finds that stability beyond the expiration date is surprisingly long-term.

Supercomputer Network Allows for Faster Genomic Analysis

October 4th 2012

A new supercomputer-based network will allow physicians to transfer and analyze genomic data more rapidly than standard methods.

Tivantinib Study Halted Following Interim Analysis

October 3rd 2012

The phase III MARQUEE trial examining tivantinib has been halted following a planned interim analysis because it was not expected to meet its primary endpoint.

Smartphone Apps

October 2nd 2012

There now are many phone-based "self-help" tools.

FDA Approves Regorafenib for Advanced Colorectal Cancer

September 27th 2012

The FDA has approved regorafenib, an oral multikinase inhibitor, to treat patients with metastatic colorectal cancer whose disease has progressed after prior therapy.

Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast Cancer

September 20th 2012

Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer.

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

September 19th 2012

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Final Results of Abiraterone Acetate in Advanced Prostate Cancer Show Significantly Improved Survival

September 18th 2012

Abiraterone acetate significantly improved overall survival with positive responses seen in several subgroups of patients with metastatic castration-resistant prostate cancer.

TH-302 Shows Non-Significant Improvement in OS for Advanced Pancreatic Cancer

September 17th 2012

A secondary analysis of a combination of an investigational hypoxia-targeted agent called TH-302 with gemcitabine slightly improved overall survival, but the results were not statistically significant.